Palo Alto

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 10, 2021
PALO, Company, Employment, Patient, Science, Twitter, Plan, LinkedIn, Cancer, Nasdaq, Lists of diseases, GLOBE, Pharmaceutical industry

All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan (the Plan).

Key Points: 
  • All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • BridgeBio Pharma (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.
  • BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.

Health Gorilla Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

Retrieved on: 
Thursday, December 9, 2021
SVP, GLOBE, Digital, API, Health, Growth, General Catalyst, Catalysis, CB Insights, Patient, Industry, Organization, VC, 150, Investment, CB, Public Health Information Network, Digital health, Cassette tape

Palo Alto, California, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CB Insights today named Health Gorilla to its third annual Digital Health 150 , which showcases the 150 most promising private digital health companies in the world.

Key Points: 
  • Palo Alto, California, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CB Insights today named Health Gorilla to its third annual Digital Health 150 , which showcases the 150 most promising private digital health companies in the world.
  • This years Digital Health 150 was unveiled live during CB Insights annual Future of Health event.
  • "We are excited to be featured in CB Insights annual Digital Health 150 list," said Steve Yaskin CEO and Co-founder of Health Gorilla.
  • 2021 Digital Health 150 Investment Highlights:
    Unicorns: 17 of the 150 companies (11%) are valued at or above $1B as of their latest funding rounds.

Xage Partners with Iron Bow to Secure Digital Transformation Efforts for the Federal Government

Retrieved on: 
Thursday, December 9, 2021
Trust, GLOBE, Iron, Technology, IAM, PALO, 2020 United States federal government data breach, OT, Access management, CEO, Pressure, Identity, Innovation, Partnership, Computer security, Customer identity access management, Government, Education, Department, Maintenance, Ice protection system, Adoption, Federation, U.S. Department of Defense Strategy for Operating in Cyberspace, DOD, Solution, ICS, Public sector, Investment, Federal, Online shopping, Risk management

The Xage Fabric is a key enabler of Iron Bows best-in-class cybersecurity solutions, which underpin the Federal Governments adoption of zero trust architectures for digital transformation.

Key Points: 
  • The Xage Fabric is a key enabler of Iron Bows best-in-class cybersecurity solutions, which underpin the Federal Governments adoption of zero trust architectures for digital transformation.
  • Following a series of notable cyberattacks over the past year, the Federal Government is enhancing security requirements for agencies.
  • Combined with Iron Bows offerings which aid digital transformation, Xage will simultaneously help agencies working with Iron Bow, including the DOD, upgrade their security postures.
  • The Xage Fabric accelerates and simplifies the way enterprises secure, manage and transform digital operations across OT, IT and cloud.

Indeni Cloudrail Partners With HashiCorp To Enable Continuous Compliance For Infrastructure as Code

Retrieved on: 
Thursday, December 9, 2021
CIS, GLOBE, Technology, Infrastructure, PCI, Organization, Partnership, HashiCorp, HIPPA, SAN, Workflow, Video game console

Indeni Cloudrail is a tool that analyzes HashiCorp Terraform Enterprise files to help cloud engineers identify security issues in their code, and identify drifts between code and live environments, enabling Continuous Security.

Key Points: 
  • Indeni Cloudrail is a tool that analyzes HashiCorp Terraform Enterprise files to help cloud engineers identify security issues in their code, and identify drifts between code and live environments, enabling Continuous Security.
  • The integration between Cloudrail and HashiCorp Terraform Enterprise allows developers to scan infrastructure-as-code files within their GitOps pipelines so they can identify and resolve issues earlier in development.
  • We welcome Indeni as a new partner and are excited about the new Cloudrail integration to HashiCorp Terraform Enterprise, said Asvin Ramesh, Sr. Director, Alliances at HashiCorp.
  • Indeni Cloudrail is a tool that can run natively in several places of your developers workflow.

Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Autoinjector, Investor, Forward-looking statement, Research, Hormone, SEC, Technology, Southern Transcon, Safety, Patient, Science, COVID-19, Annual report, Investment, Fine chemical, Pharmaceutical industry

A live webcast of the event will be available on the Investors & News section of the Ascendis Pharma website at https://ascendispharma.com .

Key Points: 
  • A live webcast of the event will be available on the Investors & News section of the Ascendis Pharma website at https://ascendispharma.com .
  • Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives.
  • Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma Group.

Benetech Names Ayan Kishore Chief Executive Officer

Retrieved on: 
Tuesday, December 7, 2021
Benetech, GLOBE, Chairperson, Technology, PALO, Volunteering, CEO, Software, Partnership, Education, Disability, Work, Employment, Literacy, Russell Reynolds, Leadership, Student, Management, Tutoring, Medicine

BenetechsBoard ofDirectorspartneredwith Russell Reynolds Associatestofinda leader who exemplified and demonstrated the inclusive and visionary leadership desired byBenetech.Kishorewasunanimouslyapproved by the board from a pool of highly qualified anddiverse applicants.

Key Points: 
  • BenetechsBoard ofDirectorspartneredwith Russell Reynolds Associatestofinda leader who exemplified and demonstrated the inclusive and visionary leadership desired byBenetech.Kishorewasunanimouslyapproved by the board from a pool of highly qualified anddiverse applicants.
  • Benetech, apioneerin tech for social impact,has beensuccessfulinbuilding andusingsoftwareto makeinformation and learningaccessiblefornearlyamillion peoplein need so far.We are well-positionedand committedto scalingourimpacttomeet the immenseneedand opportunity, saidKishore.
  • I amexcitedto leadthe organization alongwith ourexperiencedBoard of DirectorsandAdvisory Council, and ourdedicatedBenetechstaff,volunteers, and users.
  • In conjunction withKishoreassuming the CEO role:
    Christy Chin, interim CEO and Board Chair,will shift toan active board member.

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Retrieved on: 
Tuesday, December 7, 2021
European Union, Aggressive lymphoma, Medicine, Forward-looking statement, GLOBE, B-cell lymphoma, Drug Quality and Security Act, European Commission, Therapy, PALO, Ovarian cancer, MYC, Form 10-K, Mantle cell lymphoma, Union, Failure, FIH, Patient, Royal commission, 8-K, Biomarker, Securities Exchange Act of 1934, Cancer, Securities Act of 1933, COVID-19, Diagnosis, Nasdaq, Society, Pharmaceutical industry, Risk management

The granting of Orphan Drug Designation for VIP152 in DLBCL realizes another significant regulatory milestone for Vincerx, said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.

Key Points: 
  • The granting of Orphan Drug Designation for VIP152 in DLBCL realizes another significant regulatory milestone for Vincerx, said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.
  • Vincerx is currently advancing Phase 1b studies of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors.
  • Arm 1 will enroll up to 40 patients with relapsed/refractory aggressive lymphoma, including DLBCL, transformed follicular lymphoma, and mantle cell lymphoma.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Rubrik Delivers Cyber Threat Hunting in Battle Against Ransomware

Retrieved on: 
Tuesday, December 7, 2021
Zero, Cortex, Cloud, AWS, Multi-factor authentication, Microsoft Exchange, SAP HANA, Twitter, Microsoft Azure SQL Database, GLOBE, SOAR, API, Automation, Palo Alto Networks, PALO, Product strategy, Infrastructure, SQL, MFA, IBM Power Systems, Discovery, Information privacy, Organization, Computer security, SharePoint, Gathering of personally identifiable information, IDC, Intelligence, Policy, PII, Time, SAP, UI, LinkedIn, Archive, Solution, Software as a service, Microsoft, Weapon, Risk management, Software, Online shopping, Computer data storage

*1

Key Points: 
  • *1
    Recently, organizations have been targeted more frequently by highly sophisticated cyber attacks that exploit vulnerabilities in legacy backup products, forcing a ransomware payment, said Dan Rogers, President of Rubrik.
  • Now with Rubrik threat hunting, organizations can directly scan their backups for indicators of compromise, including ransomware.
  • Additionally, Rubriks new threat hunting capabilities integrate with Cortex XSOAR threat hunting playbooks for easy identification of compromised data within backup snapshots during post-incident reviews and for simplified reporting to external regulatory agencies.
  • With Rubriks latest ransomware recovery and cyber threat hunting capabilities, theyre continuing to instill confidence among customers that their data is recoverable and secure in the event of a cyber attack.

Rubrik Delivers New Data Security and Ransomware Recovery Solutions built on Microsoft Azure

Retrieved on: 
Tuesday, December 7, 2021
Zero, Cloud, Twitter, Risk, Architecture, GLOBE, Technology, PALO, Discovery, Industry, Organization, Cyberattack, Azure, Microsoft Azure, LinkedIn, Software as a service, Microsoft, Online shopping, Entertainment

This is a key milestone in our commitment to integrate Rubrik Data Security capabilities with Microsoft to deliver Zero Trust Data Security to global enterprise customers.

Key Points: 
  • This is a key milestone in our commitment to integrate Rubrik Data Security capabilities with Microsoft to deliver Zero Trust Data Security to global enterprise customers.
  • With Rubrik Cloud Vault, organizations benefit from Rubrik Zero Trust Security enhanced with the highly available, durable, secure and scalable Azure platform.
  • Rubrik, the Zero Trust Data Security CompanyTM, delivers data security and operational resilience for enterprises.
  • Rubriks big idea is to provide data security and data protection on a single platform, including Zero Trust Data Protection, Ransomware Investigation, Incident Containment, Sensitive Data Discovery, and Orchestrated Application Recovery.

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

Retrieved on: 
Monday, December 6, 2021
Patient, Regression dilution, Nasdaq, Security (finance), Disclosure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Review, Safety, Behavior, University of Oxford, Risk, CMC, Inflammation, Private Securities Litigation Reform Act, Health care, Company, PALO, Form, Adalimumab, MHRA, Clinical trial, Injection, List of life sciences, U.S. Securities and Exchange Commission, Manuscript, Pain, Hardness, Research, GLOBE, FDA, Growth, Fibrosis, Drug development, NASDAQ, Medication, Food, Pharmaceutical industry

Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated, We believe the Phase 2b clinical trial for Dupuytrens disease using adalimumab was a phenomenal achievement, having met both primary and secondary endpoints by significantly diminishing the hardness and size of the Dupuytrens nodules, respectively.

Key Points: 
  • Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated, We believe the Phase 2b clinical trial for Dupuytrens disease using adalimumab was a phenomenal achievement, having met both primary and secondary endpoints by significantly diminishing the hardness and size of the Dupuytrens nodules, respectively.
  • We believe these results affirm our teams scientific and clinical expertise and fundamentally position us to be a major leader in fibrosis therapies.
  • Both the primary and secondary clinical trial endpoints from the Phase 2b clinical trial for patients with early-stage Dupuytrens were statistically significant.
  • Any further disclosures of the clinical data may disqualify the trial from publication, a situation the Company wishes to avoid.